Trials / Completed
CompletedNCT00345163
A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)
A Phase II, Multicenter, Randomized, Non-Comparative Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme in First or Second Relapse
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 167 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, open-label, multicenter, randomized, non comparative study consisting of two concurrent single-arms. Approximately 160 subjects will be randomized in a 1:1 ratio to Arm 1 (bevacizumab alone) or Arm 2 (bevacizumab + irinotecan).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | Intravenous repeating dose |
| DRUG | irinotecan | Intravenous repeating dose |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2006-06-27
- Last updated
- 2017-05-16
Source: ClinicalTrials.gov record NCT00345163. Inclusion in this directory is not an endorsement.